BiotechTube

Group A + Group B

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bronchiectasis Adult

Conditions

Bronchiectasis Adult

Trial Timeline

Jun 1, 1996 → Sep 7, 1999

NCT ID
NCT03383939

About Group A + Group B

Group A + Group B is a pre-clinical stage product being developed by Bayer for Bronchiectasis Adult. The current trial status is completed. This product is registered under clinical trial identifier NCT03383939. Target conditions include Bronchiectasis Adult.

What happened to similar drugs?

1 of 10 similar drugs in Bronchiectasis Adult were approved

Approved (1) Terminated (2) Active (8)
✅Aztreonam lysineGilead SciencesApproved
❌Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
🔄Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3
🔄Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + PlaceboNovartisPhase 3
🔄AZLI + PlaceboGilead SciencesPhase 3
🔄AZLI + PlaceboGilead SciencesPhase 3
🔄HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03383939Pre-clinicalCompleted

Competing Products

20 competing products in Bronchiectasis Adult

See all competitors
ProductCompanyStageHype Score
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
32
AZD9668 + PlaceboAstraZenecaPhase 2
35
AZD5069 + PlaceboAstraZenecaPhase 2
35
AZD0292AstraZenecaPhase 2
42
TIP + TIP and placebo + PlaceboNovartisPhase 2
35
Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3
40
Placebo to Ciprofloxacin DPI (BAYQ3939)NovartisPre-clinical
26
Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + PlaceboNovartisPhase 3
40
QBW251 + PlaceboNovartisPhase 2
27
Ciprofloxacin (Cipro, BAYQ3939) + PlaceboNovartisPhase 2
35
AZLI + PlaceboGilead SciencesPhase 3
40
Aztreonam lysineGilead SciencesApproved
35
AZLIGilead SciencesPhase 2
35
AZLI + PlaceboGilead SciencesPhase 3
40
Itepekimab (SAR440340) + PlaceboSanofiPhase 2
35
CSL787 + PlaceboCSLPhase 1
29
CSL787 + PlaceboCSLPhase 2
42
HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3
47
HSK31858 + placeboHaisco Pharmaceutical GroupPhase 2
35
BAY85-8501 + PlaceboBayerPhase 2
32